1394166-08-5

Upstream product

• 58113-30-7 4-(3-chloropropoxy)-3-methoxyacetophenone 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 

Downstream Products

• 1456775-39-5 C₃₃H₂₉Cl₂FN₆O₆ 

Relevant academic research and scientific papers

Quinoxalinone-containing 4-phenoxy substituted quinoline compound and application thereof

The invention relates to quinoxalinone-containing 4-phenoxy substituted quinoline derivatives shown as a general formula I and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, wherein the substituent groups Ar, R1, R2 and n have meanings as shown in the description. The invention further relates to a compound with the general formula I having a strong effect of inhibitingc-Met kinase, and further relates to application of the compounds and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of medicines for treating and/or preventing diseases caused by abnormal high expression of the c-Met kinase, particularly application in preparation of medicines for treating and/or preventing cancers.

4-phenoxyl substituted quinoline compound containing 2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one and imidazole and application of compound

The invention relates to a quinoline derivative shown as the general formula I and containing 2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one and imidazole, and pharmaceutically acceptable salt, hydrate, solvate or prodrug of the quinoline derivative. In the general formula I, Ar, R1, R2, L, and n have meanings as the description defined. The invention further relates to a great c-Met kinase inhibiting effect of the compound shown as the general formula I, and applications of pharmaceutically acceptable salt, hydrate, solvate or prodrug of the compound to prepare medicines for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, particularly an application of preparing a medicine for treating and/or preventing cancer.

Dihydropyridazinone containing quinoline compound and use thereof

The invention relates to a dihydropyridazinone containing quinoline derivative shown as general formula I and its pharmaceutically acceptable salt, solvate or prodrug. Specifically, the substituents AR, R1, R2, R3, X, Y and n have the meaning given in the specification. The invention also relates to the strong c-Met kinase inhibition effect of the compound shown as the general formula I, and also relates to use of the compound and its pharmaceutically acceptable salt, solvate or prodrug in preparation of drugs treating and/or preventing diseases caused by c-Met kinase abnormal high expression, especially the use in preparation of drugs treating and/or preventing cancers. (formula I).

Containing 1, 2, 3-triazole quinoline compound and its preparation method and application

The invention relates to a quinoline derivative containing 1,2,3-triazole of the formula I as shown in the specification, and a pharmaceutically acceptable salt, solvate or prodrug of the quinoline derivative, and in the formula I, substituent groups Ar, R1, R2, R3, X, Y and n are defined as shown in the specification. The invention further relates to a compound of the formula I, and the compound has a relatively high function of inhibiting c-Met tyrosine kinase. Furthermore, the invention further relates to an application of the compound as well as a pharmaceutically acceptable salt, solvate or prodrug of the compound in preparing a medicine for treating and/or preventing diseases caused by abnormal high-expression c-Met tyrosine kinase, and particularly an application in preparing a medicine for treating and/or preventing cancer.

Quinoline compound and its preparation method and application (by machine translation)

The invention relates to the general formula I shown quinoline derivatives and their pharmaceutically acceptable salt, hydrate, solvate and prodrug, wherein substituent R1 , R2 , X, Y, Z, n has the meaning given in the specification. The invention also relates to the compounds of the general formula I has strong inhibition of c - Met kinase function, and also relates to the compounds and its pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof in the preparation of the treatment because the c - Met kinase abnormal high expression of diseases caused by the use of the medicaments, in particular in preparing and treating and/or preventing cancer of the use of the medicament. (by machine translation)

2-aryl-substituted quinoline compound and use thereof

The invention provides 2-aryl-substituted quinoline compounds and application thereof. The invention relates to quinoline derivatives represented by a general formula I as described in the specification and pharmaceutically acceptable salts, solvates and prodrugs thereof. In the general formula I, substituent Ar, R1, R2, R3, R4, X, L and n are defined in the specification. The invention further relates to the strong c-Met kinase inhibiting effect of the compounds represented by the general formula I and to application of the compounds and the pharmaceutically acceptable salts, solvates and prodrugs thereof in preparation of drugs used for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, especially in preparation of drugs used for treating and/or preventing cancers.

NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS

The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Design, synthesis and biological evaluation of novel 6,7-disubstituted-4- phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors

A series of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against H460, MKN-45, HT-29 and MDA-MB-231 cancer cell lines in vitro. Most compounds displayed good to excellent potency against four tested cancer cell lines as compared with foretinib. The SAR analyses indicated that compounds with halogen groups, especially fluoro groups at 4-position on the phenyl ring (moiety B) were more effective than those with nitro groups or methoxy groups. In this study, a promising compound 33 (c-Met IC50 = 1.63 nM) was identified, which showed the most potent antitumor activities with IC50 values of 0.055 μM, 0.071 μM, 0.13 μM, and 0.43 μM against H460, MKN-45, HT-29 and MDA-MB-231 cell lines, respectively.

QUINOLINE AND CINNOLINE COMPOUNDS AND USE THEREOF

The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Quinoline and cinnoline derivatives and their applications

The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.